Food Supplementation With Eufortyn Colesterolo Plus for LDL Modulation in Subjects With Polygenic Hypercholesterolemia (ANEMONE)

University of Bologna

Status

Completed

Conditions

Hypercholesterolemia

Treatments

Dietary Supplement: Eufortyn Colesterolo Plus

Dietary Supplement: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT04574505

SCH 01/2020

Details and patient eligibility

About

This is a two-arm randomized, placebo-controlled, double-blind, monocentric parallel-groups clinical study conducted in Italy.

The objective of this study is to evaluate the effect of dietary supplementation of a combined supplement containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara cardunculus) and Cynara scolimus, associated with high coenzyme Q10 bioavailability (Q10 phytosome® Ubiqsome) and zinc, on the glycometabolic structure of subjects with suboptimal levels of LDL cholesterolemia compared with placebo.

Enrollment

60 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects agree to participate in the study and having dated and signed the informed consent form.
Subjects who have the capability to communicate, to make themselves understood, and to comply with the study's requirements.
Male or female aged ≥ 18 years and ≤ 70 years old.
LDL-Cholesterol plasma levels >115 mg/dL and < 190 mg/dL.
TG<400 mg/dL.
Subjects who, according to the SCORE charts, have a low or moderate cardiovascular risk (defined as a total cardiovascular risk < 5%) and for whom, according to ESC/EAS guidelines 2019, the intervention strategy does not require a pharmacological lipid lowering intervention.

Exclusion criteria

Subjects already affected by cardiovascular diseases (secondary prevention) or with estimated 10 years cardiovascular disease risk> 5%;
Obesity (BMI>30 kg/m2) or diabetes mellitus;
Assumption of lipid lowering drugs or food supplements, or drugs potentially affecting the lipid metabolism;
Antihypertensive treatment not stabilized since at least 3 months;
Anticoagulants therapy
Uncontrolled hypertension (systolic blood pressure> 190 mmHg or diastolic arterial pressure> 100 mmHg);
Known current thyroid, gastrointestinal or hepatobiliary diseases;
Any medical or surgical condition that would limit the patient adhesion to the study protocol;
Abuse of alcohol or drugs (current or previous);
History of malignant neoplasia in the 5 years prior to enrolment in the study;
History or clinical evidence of inflammatory disease such as severe arthritis, systemic lupus erythematosus or chronic inflammatory diseases or current therapy with immunosuppressive agents or long-term glucocorticoids;
History or clinical evidence of any significant concomitant disease that could compromise the safety of the subject or the possibility of completing the study;
Known previous intolerance to one component of the tested nutraceuticals
Women in fertile age not using consolidated contraceptive methods
Pregnancy and Breastfeeding.